Key Research & Evidence: BPC-157 vs TB-500 Any honest appraisal of BPC-157 vs TB-500 has to begin with a caveat: almost the entire evidence base is preclinical
Patients should not independently stop therapy without discussing the plan with their care team, because abrupt interruption may affect glucose control or other treatment goals
- Overview Amneal Pharmaceuticals Inc
A 1993 study by Uno and Kurata found that a similar copper-binding peptide (PC1031) increased follicular enlargement when applied to the back skin of fuzzy rats
The formula is free from gluten, dairy and soy but contains gelatin, so its not suitable for vegetarians or vegans
[PUBMED Abstract] Long GV, Luke JJ, Khattak MA, et al.: Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial